Regeneron Pharmaceuticals, Inc. company logo

# RNN 1st Gen Model Regeneron Pharmaceuticals, Inc. Pharmaceutical preparations

Prediction models:
Subscribe >> Deal exit on
Feb. 22, 2018
Deal entry on
Feb. 22, 2018
4.66%Expected margin
66.18% successful of 68 deals
$ 315.75 Last close price
at 22-feb-2018

REGN

Model's trade recommendations -8.48% Return for period

-8.96% Annual return

$34.79B Market Cap

β 1.47  

REGN

Model (following trade recommendations)

REGN

Underlying stock

S&P 500

Index
Return for period -8.48%
-19.42%
1.78%
52wk return -12.08%
-12.52%
16.82%
52wk Range
315.75—526.53
2000.54—2399.63
Sortino ratio -0.51
Sharpe ratio -0.45
Norm. RMSE 1.03%
Downside risk 15.67%
Volatility 17.91%
  • BUY Analysts consensus recommendation

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma and has preclinical programs in other diseases and disorders.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Regeneron Pharmaceuticals, Inc. (REGN) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for REGN model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 96M
P/E 23.38
Shares Outstanding 108M
% Held by Insiders 10.80%
% Held by Institutions 64.67%
EPS (last reported FY) $13.41
EPS (last reported Q) $4.46
EPS, estimated (last reported Q) $4.18
Total revenues $6 B
Net income $1 B